Media stories about Diplomat Pharmacy (NYSE:DPLO) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.5229264770011 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- 5 Low Leverage Stocks to Buy Amid Rate Hike Woes (finance.yahoo.com)
- Cancer Genetics (CGIX) vs. Diplomat Pharmacy (DPLO) Financial Contrast (americanbankingnews.com)
- Q1 2019 Earnings Estimate for Diplomat Pharmacy Inc (DPLO) Issued By William Blair (americanbankingnews.com)
- Diplomat Pharmacy (DPLO) Price Target Raised to $26.00 (americanbankingnews.com)
Several equities research analysts have recently commented on the company. Needham & Company LLC boosted their price target on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Leerink Swann raised Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research note on Monday, December 11th. Deutsche Bank assumed coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They set a “buy” rating and a $22.00 price target on the stock. Robert W. Baird lowered Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $18.00 in a research note on Thursday, November 16th. Finally, BidaskClub lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of “Buy” and an average target price of $20.94.
Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the company earned $0.21 EPS. Diplomat Pharmacy’s revenue was down 4.8% on a year-over-year basis. research analysts expect that Diplomat Pharmacy will post 0.85 earnings per share for the current fiscal year.
In related news, President Joel Saban bought 10,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The shares were purchased at an average price of $15.24 per share, with a total value of $152,400.00. Following the purchase, the president now owns 12,000 shares in the company, valued at $182,880. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey G. Park bought 3,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was bought at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the purchase, the director now owns 7,640 shares in the company, valued at approximately $118,114.40. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 15,000 shares of company stock worth $228,780. 30.20% of the stock is owned by corporate insiders.
WARNING: This piece was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-diplomat-pharmacy-dplo-share-price/1833849.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with our FREE daily email newsletter.